GEHC
GE HealthCare
$60.64
▼ 1.5%Updated Today 7:15 PM ET
▼ Down 14.3% over the last 12 months
Market Cap
$28.02B
P/E
15.02x
Forward P/E (est.)
17.12x
ROE
18.8%
Revenue Growth
6.0%
EPS Growth
-12.3%
Profit Margin
9.1%
FCF Yield
7.7%
Debt / Equity
0.97x
ROIC
10.0%
Interest Coverage
—
Current Ratio
1.22x
Dividend Yield
0.2%
Implied Growth (rev. DCF)
3.4%
Rating Score
51/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what GEHC's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. GEHC trades near $60.64, below its 50-day average ($65.64) and 200-day average ($74.69). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 44 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. GEHC's is $1.76 (~2.9% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month GEHC found buyers near $60.73 (support) and sellers near $66.44 (resistance); its 52-week range is $58.75–$89.77. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.1× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
GE HealthCare (GEHC) is a large-cap company in the Health Care Equipment industry, part of the Health Care sector of the S&P 500, with a market value around $28.02B.
In its latest reported year it generated about $20.63B in revenue and $2.08B in net profit.
Our model rates GEHC Neutral (51/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
4.1%
Revenue moved from $17.59B in 2021 to $20.63B in 2025, a 4.1% compound annual growth rate. The most recent year grew a steady 6.0% year over year. Slower, mature growth is common for established businesses.
Gross Margin
40.0%
Operating Margin
13.4%
Net Margin
10.1%
ROE
18.8%
GE HealthCare keeps about 9.1% of each sales dollar as net profit, with a 40.0% gross margin and 13.4% operating margin. Return on equity is 18.8% and return on invested capital about 10.0%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$10.13B
Net Debt
$7.87B
Net Debt / EBITDA
2.85x
Debt / Equity
0.97x
Leverage: debt-to-equity is 1.0x, with a current ratio of 1.2x. That is a moderate, manageable debt load for most businesses. It carries roughly $10.13B of total debt against $2.26B of cash.
Operating CF
$1.99B
Free Cash Flow
$1.50B
FCF Margin
7.3%
In the latest year GE HealthCare produced about $1.99B of operating cash flow and $1.50B of free cash flow after capital spending. That is a free-cash-flow yield of about 7.7% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
15.02x
P/S
1.43x
P/B
3.51x
EV / EBITDA
—
GEHC trades at 15.0x trailing earnings (about 17.1x on estimated forward earnings), 1.4x sales, and 3.5x book value. Reverse-engineering today's price implies the market expects roughly 3.4% long-term free-cash-flow growth. That is a fairly typical valuation for a profitable company.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How GEHC stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), GEHC ranks #33 of 59 by our overall rating. It trades at a discount versus the sector on earnings (15x P/E vs. 25.4x median) with a higher return on equity (18.8% vs. 14.9%) and slower revenue growth (6.0% vs. 7.9%).
P/E vs sector
15x
median 25.4x
ROE vs sector
18.8%
median 14.9%
Growth vs sector
6.0%
median 7.9%
Sector rank
#33
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$54.61 – $91.01
vs. $60.64 today · expected CAGR -2% – 8%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $21.86B | $23.17B | $24.56B | $26.04B | $27.60B |
| Net income | $2.19B | $2.32B | $2.46B | $2.60B | $2.76B |
| EPS | $4.81 | $5.09 | $5.40 | $5.72 | $6.07 |
| Share price (low) | $43.25 | $45.85 | $48.60 | $51.52 | $54.61 |
| Share price (high) | $72.09 | $76.42 | $81.00 | $85.86 | $91.01 |
| CAGR (low–high) | -29% / 19% | -13% / 12% | -7% / 10% | -4% / 9% | -2% / 8% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for GEHC:
- Strong return on equity (18.8%) shows capital is put to work well.
- Healthy free-cash-flow yield (~7.7%) funds buybacks and dividends.
The case against GEHC:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: GE HealthCare is a large-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at 15.0x earnings, which our model scores Neutral (51/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.